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The Journal of Immunology
Evidence for the Existence of a CXCL17 Receptor Distinct
from GPR35
Nurul A. S. Binti Mohd Amir,*,† Amanda E. Mackenzie,‡ Laura Jenkins,‡
Karim Boustani,* Marston C. Hillier,* Tomoko Tsuchiya,x Graeme Milligan,‡ and
James E. Pease*,†
The chemokine CXCL17 is associated with the innate response in mucosal tissues but is poorly characterized. Similarly, the G
protein–coupled receptor GPR35, expressed by monocytes and mast cells, has been implicated in the immune response, although
its precise role is ill-defined. A recent manuscript reported that GPR35 was able to signal in response to CXCL17, which we set out
to confirm in this study. GPR35 was readily expressed using transfection systems but failed to signal in response to CXCL17 in
assays of b-arrestin recruitment, inositol phosphate production, calcium flux, and receptor endocytosis. Similarly, in chemotaxis
assays, GPR35 did not confirm sensitivity to a range of CXCL17 concentrations above that observed in the parental cell line. We
subsequently employed a real time chemotaxis assay (TAXIScan) to investigate the migratory responses of human monocytes and
the monocytic cell line THP-1 to a gradient of CXCL17. Freshly isolated human monocytes displayed no obvious migration to
CXCL17. Resting THP-1 cells showed a trend toward directional migration along a CXCL17 gradient, which was significantly
enhanced by overnight incubation with PGE2. However, pretreatment of PGE2-treated THP-1 cells with the well-characterized
GPR35 antagonist ML145 did not significantly impair their migratory responses to CXCL17 gradient. CXCL17 was susceptible to
cleavage with chymase, although this had little effect its ability to recruit THP-1 cells. We therefore conclude that GPR35 is
unlikely to be a bona fide receptor for CXCL17 and that THP-1 cells express an as yet unidentified receptor for CXCL17. The
Journal of Immunology, 2018, 201: 000–000.
I
ntensive efforts by the chemokine research community over
the last two decades have identified a family of around 45 such
proteins in the human, noted for their ability to induce the
directional migration (i.e., chemotaxis) of leukocytes (1). Con-
siderable progress has been made regarding our understanding of
this family and how the signals they induce via specific G protein–
coupled receptors (GPCRs) shape the immune responses of the
host (2). In the case of the chemokine receptors CCR5 and CXCR4,
this knowledge has been successfully translated into medicines with
clinical efficacy in the treatment of HIV infection, the treatment
of WHIM (warts, hypogammaglobulinemia, immunodeficiency, and
myelokathexis) syndrome, and the mobilization of stem cells (3–5).
Despite this progress, within the chemokine family there still re-
mains a small number of orphan chemokines for which no specific
GPCR partners have been identified. These include the CXC
chemokines CXCL14 (6, 7) and CXCL17 (8).
CXCL17 was first described in the literature as a monocyte-
recruiting chemokine (8), and its overexpression has been shown
to promote the growth of a variety of tumors in vivo (9, 10). In
humans, CXCL17 appears to have roles in both homeostatic and
inflammatory settings. Its expression is restricted to mucosal sites,
including the small intestine, trachea, and lung, where it is asso-
ciated with a broad spectrum of antimicrobial function, albeit
when at micromolar concentrations of chemokine (11). Notably,
CXCL17 was undetectable in the bronchioalveolar lavage of
healthy subjects but expressed at significant levels in the bron-
chioalveolar lavage of patients suffering from idiopathic pulmo-
nary fibrosis (IPF) (11). This prompted the authors of that study to
speculate that CXCL17 plays a role in microbial killing within the
IPF lung (often associated with infection in advanced stages of
the disease) or is involved with the associated remodeling via the
recruitment of myeloid cells. Consistent with this latter hypothe-
sis, the same group went on to generate a CXCL17-deficient
mouse model that was notable for the reduced levels of macro-
phages observed in the lung under homeostatic conditions (12).
GPR35 was originally identified in the laboratory of O’Dowd
(13) as an open reading frame predicted to encode a GPCR.
Subsequent demonstration that it is expressed by various cells of
the immune system has led to the suggestion that it may have
potential as a therapeutic target in inflammatory disease (14, 15).
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In human, two distinct GPR35 isoforms known as GPR35a and
GPR35b are expressed, with GPR35b differing from GPR35a by
the presence of an additional 31 aa at the N terminus (16), anal-
ogous to the two N-terminally spliced isoforms of the chemokine
receptor CXCR3 (17). Endogenous ligands identified as activating
GPR35 include the tryptophan metabolite kynurenic acid (18) and
various lysophosphatidic acids (19), although the millimolar
concentrations of the former ligand needed to induce signaling at
human GPR35 has led to questions about the physiological rele-
vance of the original finding (20). Among synthetic compounds,
the asthma medications cromolyn disodium (21) and lodoxamide
(22), which serve to stabilize mast cells, have also been shown to
be agonists of GPR35, implicating GPR35 in the allergic response.
Recently, Maravillas-Montero et al. (23) described CXCL17 as a
GPR35 ligand with nanomolar activity in both chemotaxis and
intracellular calcium flux assays. In this article, we describe an
investigation into the potency and specificity of CXCL17 as a
GPR35 ligand using a battery of in vitro assays in both GPR35
transfected cell lines, human monocytes, and the human myeloid
cell line THP-1.
Materials and Methods
Materials
Materials were purchased from Thermo Fisher Scientific (Paisley, U.K.)
unless otherwise described. Recombinant human CXCL17 generated in
Escherichia coli was purchased from R&D Systems (Abingdon, U.K.) and
was comprised of the 96 aa Leu24–Leu119. A plasmid containing an insert
encoding a 3xHA-tagged GPR35a cDNA (catalog no. GPR035TN00) was
purchased from the cDNA Resource Center (Bloomsburg University,
Bloomsburg, PA) and is an N-terminal 3xHA-tagged variant of the GPR35
plasmid that was derived by PCR from the clone used by Maravillas-
Montero et al. (23). The insert was resequenced by Eurofins MWG
(Ebersberg, Germany) and found to be authentic. Other cDNAs encoding
human GPR35a and GPR35b as well as the mouse and rat orthologs of
GPR35 have been detailed previously (20). The GPR35 antagonist ML145
was purchased from Bio-Techne (Oxford, U.K.) and was originally iden-
tified as a GPR35 inhibitor by a group from the Sanford-Burnham Center
for Chemical Genomics using an arrestin recruitment assay (bioassay
identifier: 2079) (24). The murine anti-hemagglutinin (HA) mAb (HA.11)
was purchased from Cambridge Bioscience (Cambridge, U.K.). CCL2,
CCL15, and CCL23 were purchased from PeproTech EC (London, U.K.)
Cell culture
The mouse pre–B cell line L1.2 and THP-1 cells were cultured in RPMI
1640 (Sigma-Aldrich, Dorset, U.K.) containing 10% FBS, penicillin/
streptomycin, MEM nonessential amino acids, sodium pyruvate, and 2-ME
and incubated at 37˚C, 5% CO2. Cells were maintained in this medium at a
concentration of 0.5 3 106 cells/ml. Human embryonic kidney (HEK) 293
T cells were maintained in DMEM supplemented with 0.292 g/l L-glutamine,
10% (v/v) FBS, and 1% penicillin/streptomycin mixture. Peripheral blood
was taken from healthy normal subjects with informed consent according to
a protocol approved by a local ethics committee. Monocytes were isolated
by negative selection using the RosetteSep kit (StemCell Technologies,
Grenoble, France).
Cell transfections
This protocol was essentially that as previously described (25). Briefly,
1.0–1.5 3 107 cells/ml were used for each transfection in a volume of
800 ml of RPMI 1640. This was transferred to a 0.4-cm gap electroporation
cuvette, after which 50 ml of a 10 mg/ml solution of baker’s yeast tRNA
(Sigma-Aldrich) was added to the cuvette. One microgram of the GPR35
plasmid per 1 3 106 cells was added to the cuvette, and the cells were
subjected to electroporation at 330 V, 950 mF. After allowing the cells to
recover for 20 min at room temperature, cells were transferred to a flask
containing complete medium and incubated for 18 to 24 h before receptor
expression was examined by flow cytometry prior to experimentation. For
transient transfections, sodium butyrate (Sigma-Aldrich) was added to a
final concentration of 10 mM to enhance receptor expression. To generate
the L1.2 clone 23 stably expressing GPR35, cells were transfected as
before and selected after 48 h of culture by the addition of 1 mg/ml G418.
Surviving cells were expanded and cloned by limiting dilution. Clone 23
was identified by flow cytometry as expressing suitable amounts of GPR35
on its surface. Transient transfections using HEK293 T cells were per-
formed using polyethylenimine, with experiments carried out 48 h after
transfection.
Flow cytometry
Briefly, 0.5 3 106 transfected cells were used for each staining procedure.
Cell pellets were resuspended in 100 ml of FACS buffer (PBS, 0.25% BSA,
0.05% NaN3) containing primary Ab at a concentration of 10 mg/ml and
incubated for 5 min on ice. The cells were then washed with 500 ml FACS
buffer and pelleted by centrifugation (1500 3 g) for 30 s. The supernatant
was discarded, and the cell pellet was resuspended in 100 ml FACS buffer
containing FITC-conjugated secondary Ab and incubated at 4˚C for 5 min.
The cells were then washed with 500 ml FACS buffer and centrifuged
briefly as before for 30 s. The supernatant was discarded, and the cell
pellets were resuspended in 500 ml staining buffer containing TO-PRO3 at
a dilution of 1:10,000. The samples were read on a FACSCalibur flow
cytometer (Becton Dickinson, Oxford, U.K.).
Modified Boyden chamber chemotaxis assays
Assays were performed essentially as described by Vaidehi et al. (25) using
96-well disposable chemotaxis plates (Neuro Probe, Gaitherburg, MD).
Cells were allowed to migrate in response to chemokines for 5 h at 37˚C,
5% CO2, after which CellTiter-Glo (Promega, Southampton, U.K.) was
used to measure the responses via luminescence, and responses were read
from a plate reader as before (26). Data from these assays are shown as
chemotactic indices following division by the basal migratory responses to
buffer alone. In some experiments, prior to use in the assay, cells were
preincubated for 15 min at room temperature in buffer containing DMSO
(vehicle) or a 1 mM final concentration of the GPR35 antagonist ML145.
Endocytosis assay
L1.2 cells expressing 3xHA-GPR35 were resuspended in RPMI containing
0.1% BSA at 23 106 cells/ml. To 25-ml volumes of cells was added 25 ml of
the same buffer containing either 20 mM lodoxamide, 10 mM lodoxamide, 2
mM lodoxamide, or 2 mM CXCL17. Controls contained the vehicle DMSO.
For each data point, the cells were incubated for 15 min at 4˚C (to measure
basal GPR35 expression in the absence of endocytosis) and 37˚C (to measure
agonist-driven endocytosis of the receptor). GPR35 remaining on the cell
surface after treatment was quantified by flow cytometry using the anti-HA
Ab as described above.
Real-time chemotaxis assays (TAXIScan)
TAXIScan apparatus for the real time visualization of leukocyte migration
was assembled and used according to a published protocol (27). Monocytes
or THP-1 cells were allowed to migrate for 1 h at 37˚C along gradients
generated by the addition of 1 ml of either 1 mM CXCL17, 10 mM
CXCL17, or 1 mM CCL2. Cells were also allowed to migrate in the ab-
sence of a stimulus to obtain basal chemotaxis measurements. In some
experiments, prior to use, cells were preincubated for 15 min at room
temperature in buffer containing DMSO (vehicle) or 1 mM final concen-
tration of the GPR35 antagonist ML145. Sequential image data were
captured every minute as individual JPEGs, which were subsequently
processed with ImageJ (National Institutes of Health) equipped with the
manual tracking (Fabrice Cordelieres; Institut Curie, Orsay, France) and
chemotaxis tool plugins (ibidi, Martinsried, Germany).
Individual experiments consisted of triplicate or quadruplicate for each
stimulus, and data illustrated are collated from an equal number of ex-
periments as highlighted in the appropriate figure legend. The total numbers
of cells tracked under each condition are shown in the top right hand corner
of each plot. For each individual cell, the forward migration index parallel to
the gradient (FMI‖) was calculated using the chemotaxis tool plugin. FMI‖
is defined as the distance traveled by the cell in the y-axis (i.e., along the
chemokine gradient) divided by the accumulated distance traveled and is a
reliable measure of migration along a chemoattractant gradient (28).
GPR35–b-arrestin-2 interaction assays
The bioluminescence resonance energy transfer–based b-arrestin-2 re-
cruitment assays were performed using HEK293 T cells transfected tran-
siently to coexpress forms of human, mouse, or rat GPR35 along with
b-arrestin-2, as described previously (20).
Inositol phosphate assays
Chimeric G protein a subunits were as described in Jenkins et al. (20), and,
following expression in HEK293 T cells along with the described forms of
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GPR35, inositol phosphate measurements were performed as previously
described (20).
Intracellular calcium flux assays
These were performed as previously described (29) using cells that were
loaded with the dye FURA-2 AM. Real-time data were recovered using
a fluorimeter (LS-50B; PerkinElmer, Beaconsfield, U.K.). Data are
expressed as the relative ratio of fluorescence emitted at 510 nm after
sequential stimulation at 340 and 380 nm.
Chemokine digestion and SDS-PAGE analysis
Twenty micrograms of CXCL17 was resuspended in a buffer composed of
100 mM Tris-HCl (pH 7.8) and 10 mM CaCl2. The aliquot was divided into
two, with one aliquot receiving the addition of 0.1–0.4 mg of recombinant
human chymase (Sigma-Aldrich, Poole, U.K.). Both tubes were incubated
for 18 h at 37˚C before being stored at220˚C until further use. SDS-PAGE
was carried out using precast NuPAGE 4–12% Bis-Tris Protein Gels.
Samples were mixed with 23 Tris-Glycine SDS Sample Buffer and heated
to 95˚C for 10 min prior to loading alongside SeeBlue Plus2 prestained
protein standards. Gels were run at 150 V for 50 min and then fixed in 25%
isopropanol and 10% acetic acid (HOAc) for 30 min with agitation. Fixed
gels were stained with 0.25% Coomassie Brilliant Blue G-250 (Bio-Rad
Laboratories, Watford, U.K.) in 25% isopropanol and 10% HOAc for 2 h,
after which they were destained with 10% HOAc overnight. Images were
acquired with myECL Imager (Thermo Fisher Scientific).
Statistical analysis
Data analysis was carried out using GraphPad Prism version 6.0 (GraphPAD
Software, San Diego, CA). Experiments were assessed, and appropriate
statistical tests were noted in the figure legends. In all tests, p , 0.05 was
considered as statistically significant.
Results
The most widely used approach to demonstrate agonist ligand
function at GPR35 has been to measure induced recruitment to the
receptor of a b-arrestin isoform (30–33). Following cotransfection
into HEK293 T cells of the short isoform of human GPR35
(GPR35a), tagged at the C terminus with enhanced yellow
fluorescent protein (eYFP), along with a C-terminally Renilla
luciferase-tagged form of b-arrestin-2, the well-characterized
synthetic GPR35 agonist zaprinast (22, 30, 32, 34) promoted in-
teractions between the receptor and the arrestin in a concentration-
dependent fashion (Fig. 1A), with the negative logarithm of the
EC50 (pEC50) = 5.46 6 0.04 (mean 6 SEM, n = 3). In contrast, at
concentrations up to 100 nM, CXCL17 was entirely without effect
(Fig. 1A). Human GPR35 exists as two isoforms, with the longer
version possessing an extended N-terminal domain comprising an
additional 31 aa (16). As binding of chemokines to their cognate
receptors often involves key interactions within the receptor
N-terminal domain (35, 36), we next tested whether this longer
isoform of human GPR35 (GPR35b) would recruit b-arrestin-2 in
a CXCL17-dependent manner. The chemokine was also entirely
inactive in these experiments (Fig. 1B), whereas, once again,
zaprinast was an effective agonist (Fig. 1B), with pEC50 = 5.77 6
0.10 (mean 6 SEM, n = 3). To assess whether CXCL17 might
have effects at rodent orthologs of GPR35, experiments akin to
those described above were performed using either mouse (Fig. 1C)
or rat GPR35 (Fig. 1D). In these species, only a single isoform has
been identified, and this corresponds to human GPR35a (18).
However, once more, CXCL17 was inactive, whereas at each
rodent ortholog zaprinast was an effective agonist. As reported
previously (32), zaprinast was more than 10-fold more potent at
rat GPR35 (pEC50 = 7.04 6 0.03) than the mouse (pEC50 =
5.98 6 0.05) form.
Interaction with a b-arrestin reflects initial steps in desensiti-
zation and internalization of a GPCR rather than the canonical
route(s) of G protein–mediated signal transduction. To assess
whether CXCL17, although unable to promote interactions with a
FIGURE 1. Zaprinast, but not CXCL17, is able to promote interactions between b-arrestin-2 and isoforms and species orthologs of GPR35. Following
coexpression of C-terminally eYFP-tagged forms of human GPR35a (A), human GPR35B (B), mouse (C), or rat (D) GPR35 and Renilla luciferase-tagged
b-arrestin-2, the indicated concentrations of the GPR35 agonist zaprinast (filled symbols) or CXCL17 (open symbols) were added, and induced interactions
between GPCR35 and b-arrestin-2 were assessed 5 min later by measuring bioluminescence resonance energy transfer.
The Journal of Immunology 3
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b-arrestin, might still activate GPR35 but act as an entirely G
protein–biased (37) agonist, we coexpressed human GPR35a
alongside chimeric G protein a subunits (38, 39) consisting of the
backbone sequence of the G protein Gq, which allows downstream
activation of phospholipase b1 and the hydrolysis of the mem-
brane phospholipid phosphatidylinositol 4,5 bisphosphate but in
which the C-terminal 5 aa are replaced by the corresponding resi-
dues from either G13 or Gi1/2, as these are the receptor-interacting
residues of the G proteins that GPR35 has previously been shown
to be able to couple to (20). When employing the Gq–G13 chimera,
measures of inositol phosphate production showed that both
zaprinast (pEC50 = 6.57 6 0.05) (Fig. 2A) and the high-potency
agonist lodoxamide (22) (pEC50 = 9.13 6 0.24) (Fig. 2A) were
able to increase levels of inositol phosphates in a concentration-
dependent manner. Once more, CXCL17 was unable to mimic
these effects (Fig. 2A). Equivalent results were obtained when
using the Gq–Gi1/2 chimera (Fig. 2B) except at the very highest
concentration of CXCL17 used (100 nM), in which a very minor
increase in inositol phosphate production compared with the in-
crease produced by either zaprinast (pEC50 = 6.33 6 0.03) or
lodoxamide (pEC50 = 8.64 6 0.08) was detected (Fig. 2B).
However, when using GPR35b in concert with the Gq–Gi1/2
chimera, no response to CXCL17 could be detected (Fig. 2C),
whereas both zaprinast (pEC50 = 6.39 6 0.05) and lodoxamide
(pEC50 = 9.05 6 0.07) remained efficacious.
Overall, these studies indicate that at least in heterologous
transfected cell systems, CXCL17 in unable to act as an agonist for
either the long or short isoforms of human GPR35 or to function at
the corresponding rat and mouse orthologs.
Because the mouse pre–B cell line Ba/F3 had been shown pre-
viously to be successfully transfected with GPR35, we switched to
express the receptor in the mouse pre–B cell line L1.2., which
we have previously used to good effect in expressing chemokine
receptors (25). L1.2 cells were transiently transfected with a
3XHA-GPR35 plasmid, and flow cytometric analysis using an
anti-HA Ab found the construct to be very well expressed on the
cell surface (Fig. 3A). In modified Boyden chamber assays,
there was little difference in the chemotactic responses between
naive and 3XHA-GPR35 transfectants (Fig. 3B). Both GPR35
transfectants and naive L1.2 cells showed migratory responses
to 1 mM CXCL17 that were not significantly different from each
other. No chemotaxis at CXCL17 concentrations of 100 nM or
below was observed, in keeping with the pharmacological data
observed in HEK293 T cells (Figs. 1, 2).
To make our assays as robust as possible, we generated an L1.2
clone, designated clone 23, which stably expressed GPR35 at high
levels (Fig. 4A). We then used cells of this clone in assays of
chemotaxis, calcium flux, and receptor endocytosis. No significant
levels of chemotaxis in response to 1 mM CXCL17 were observed
in this line above those observed in the absence of a stimulus
(data not shown). Likewise, no calcium flux responses to 100 nM
CXCL17 were observed with this line, despite loading of the
cells with Fura-2, as denoted by the response to cell lysis with
SDS (Fig. 4B). Significant endocytosis of GPR35 in response to
1- and 10-mM concentrations of the high potency GPR35 agonist
lodoxamide (22) was observed when cells were incubated at
37˚C but not at 4˚C, suggestive of clathrin-mediated endocytosis
FIGURE 3. GPR35 is readily expressed in L1.2 cells but does not me-
diate chemotactic responses to CXCL17. (A) represents typical staining
profiles obtained for L1.2 cells transiently transfected with the 3xHA
GPR35 plasmid. Staining with isotype control is shown as an open his-
togram, and anti-HA staining is shown as a filled histogram. (B) shows the
migratory responses of GPR35 expressing L1.2 cells and naive L1.2 cells
to increasing CXCL17 concentrations in a modified Boyden chamber. Data
are shown as the mean 6 SEM from four experiments.
FIGURE 2. CXCL17 is unable to promote G protein–mediated signaling via isoforms of human GPR35. Either the short, GPR35a (A and B), or the
N-terminally extended, GPR35b (C), isoforms of human GPR35 were expressed in HEK293 cells along with the chimeric G protein a subunits Gq–G13 (A)
or Gq–Gi1/2 (B and C). Following incubation with the indicated concentrations of zaprinast (filled circles), lodoxamide (filled triangles), or CXCL17 (open
symbols) for 30 min, levels of inositol phosphates were measured.
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(Fig. 4C). Directly comparing 1-mM concentrations of lodoxamide
and CXCL17 in the same assay, we showed that lodoxamide was
able to induce significant endocytosis of GPR35, whereas CXCL17
was without activity (Fig. 4D).
Because it was possible that cells that express GPR35 endog-
enously also express other proteins lacking in HEK293 T cells that
allow CXCL17 to act as a GPR35 agonist, we turned our attention
to the study of human THP-1 cells, which were previously shown to
be responsive to CXCL17 (23). Initial experiments employed a
real-time assay of cell migration (TAXIScan) with resting cells.
THP-1 cells were introduced into the chamber and left to migrate
for 1 h without exposure to a stimulus or exposed to gradients
formed from the introduction of a 1-ml volume of 1 mM CCL2, 1
mM CXCL17, or 10 mM CXCL17. Images were taken at 1 min
intervals, and the tracks of the cells from several pooled experi-
ments are shown in Fig. 5. Although little basal migration was
observed in the absence of a stimulus (Fig. 5A), many more cells
were observed to migrate in response to 1 mM CCL2 (Fig. 5B).
Although little cell migration above basal was observed in response
to 1 mM CXCL17 (Fig. 5C), approximately three times more cells
migrated in response to 10 mM CXCL17 (Fig. 5D). Subsequent
analysis of the FMI‖ showed a significant response to 1 mM CCL2
and a trend toward significant migration toward 10 mM CXCL17
when compared with the basal levels of migration (Fig. 5E). We
subsequently repeated the TAXIScan analysis using THP-1 cells
that had been cultured overnight in the presence of PGE2 (Fig. 6)
because this treatment has been reported previously to enhance
chemotactic responses of these cells to CXCL17 (23). In com-
parison with the basal migration (Fig. 6A), we observed robust
migration of cells to 1 mM CCL2 with a 6-fold increase in the
number of migrating cells (Fig. 6B). Responses to 1 mM CXCL17
and 10 mM CXCL17 were more modest, although the migration
toward 10 mM CXCL17 appeared above that observed under basal
conditions (Fig. 6C, 6D). This was confirmed when the FMI‖
components of migration were analyzed, with the responses to
1 mM CCL2 and 10 mM CXCL17 significantly greater than the
basal response (Fig. 6E). Thus, incubation of THP-1 cells with
PGE2 increased their capacity to respond by chemotaxis to gra-
dients of CCL2 and of CXCL17.
Having established that PGE2-treated THP-1 cells could re-
spond to CXCL17 in chemotaxis assays, the question remained
whether this was mediated via GPR35, given that Maravillas-
Montero et al. (23) had shown that such treatment induces an
increase in the levels of GPR35 transcripts. We therefore exam-
ined whether the migratory responses of PGE2-treated THP-1 cells
were sensitive to ML145, a potent, selective antagonist of human
GPR35 with an IC50 value against EC80 concentrations of various
GPR35 agonists in the region of 20 nM (32). PGE2-treated THP-1
cells were incubated in buffer containing 1 mM ML145 or an
identical concentration of the DMSO vehicle, after which they
were used directly in TAXIScan assays (Fig. 7). In keeping with
our earlier analysis, whereas little directional migration was
FIGURE 4. GPR35 is endocytosed by lodoxamide but not by CXCL17.
(A) shows aAnti-HA staining of clone 23, an L1.2 line stably expressing
3xHA-GPR35 (solid histogram) with isotype control staining shown as
an open histogram. (B) shows a lack of intracellular calcium flux in
response to 100 nM CXCL17 in clone 23 cells. 0.1% SDS was used as a
positive control to lyse cells and show successful loading with the Fura-2
dye. The data shown are from a single experiment representative of four
experiments. (C) shows 3xHA-GPR35 internalization in clone 23 following
incubation with different lodoxamide (LDX) concentrations at 4˚C or 37˚C
for 15 min. (n = 3). (D) shows 3xHA-GPR35 internalization in response to
1 mM lodoxamide or 1 mM CXCL17 incubated at 4˚C or 37C for 15 min
(n = 4). Data are shown as the mean6 SEM for the number of experiments
shown in brackets. Statistical differences between controls were confirmed
by a Student t test. *p , 0.05.
The Journal of Immunology 5
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observed in the absence of a stimulus, significant numbers of cells were
observed to migrate in response to 1 mM CXCL17 (Fig. 7A–C). Pre-
exposure to the GPR35 antagonist ML145 had no inhibitory effect on
the ability of the cells to response to 1 mM CXCL17, which was
confirmed by subsequent analysis of FMI‖ component (Fig. 7D). Thus,
we conclude that although PGE2-treated THP-1 cells are able to migrate
along gradients of CXCL17, this is unlikely to be mediated by GPR35.
Because Pisabarro et al. (8) had previously shown that CXCL17 was
chemotactic for CD14+ PBMCs, we isolated primary human monocytes
and pretreated them with either vehicle (DMSO) or a final concentration
of 1 mM ML145 prior to TAXIScan assays using CXCL17 as an at-
tractant (Fig. 8). No significant migration in response to CXCL17 was
observed above that seen in the lack of a stimulus (Fig. 8A, 8C), which
was unaffected by pretreatment with ML145 (Fig. 8B, 8D, 8E).
FIGURE 5. Analysis of the migration
of THP-1 cells along chemokine gradi-
ents. (A)–(D) show the paths traveled
by individual cells in response to the
stimuli indicated. The figures show data
pooled from three experiments, with
three videos analyzed per condition.
Numbers of cells tracked for each con-
dition are shown in the top right-hand
corner of the panels. (E) shows the mean
FMI‖ 6 SEM of the data shown in
(A)–(D). Statistical differences be-
tween no stimulus and the indicated
stimuli were confirmed by a one-way
ANOVA with Bonferroni’s multiple
comparisons test. *p , 0.05.
FIGURE 6. Analysis of the migration
of PGE2-treated THP-1 cells along
chemokine gradients. (A)–(D) show the
paths traveled by individual cells in re-
sponse to the stimuli indicated. The
figures show data pooled from three
experiments, with three videos analyzed
per condition. Numbers of cells tracked
for each condition are shown in the
top right hand corner of the panels.
(E) shows the mean FMI‖6 SEM of the
data shown in (A)–(D). Statistical dif-
ferences between no stimulus and the
indicated stimuli were confirmed by a
one-way ANOVA with Bonferroni’s
multiple comparisons test. **p , 0.01,
****p , 0.0001.
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CXCL17 is unusual among chemokines in that the mature
protein (devoid of the signal peptide) contains an extended N
terminus, as also observed with the CC chemokines CCL15 and
CCL23 (Fig. 9A). Because the potency of CCL15 and CCL23 is
significantly increased by N-terminal cleavage (40), we assessed
whether this was also true for CXCL17. Mast cell chymase was
chosen as a potential proteolytic activator of CXCL17 given the
mucosal expression pattern of CXCL17 (11). In agreement with
a previous report (40), CCL15 and CCL23 were cleaved fol-
lowing incubation with recombinant human chymase (Fig. 9B),
which led to increased potency in chemotaxis assays employing
CCR1 transfectants (Fig. 9C, 9D). CXCL17 was also a substrate
for chymase (Fig. 9E), although cleavage failed to influence
the potency or efficacy of the chemokine in chemotaxis assays
employing PGE2-treated THP-1 cells across a range of CXCL17
concentrations (Fig. 9F).
Discussion
CXCL17 was the last of the CXC chemokines to be identified by
genomic analysis and was originally reported to be chemotactic for
dendritic cells and monocytes (8). The gene encoding CXCL17
resides on chromosome 19q13.2, distinct from the cluster on
chromosome 4q13.3 where the majority of the CXC chemokines
reside (1). In keeping with its discrete chromosomal location, the
functions of this chemokine are poorly understood, although its
expression appears to be restricted to mucosal tissues (11). Mice
deficient in CXCL17 have been reported to have significantly re-
duced numbers of macrophages in the lung during homeostasis,
whereas injection of CXCL17 i.p. results in increased recruitment
of macrophages to the peritoneum (12). Thus, in both loss-
of-function and gain-of-function rodent studies, CXCL17 appears
to recruit macrophages. The role of elevated levels of CXCL17
reported in the lungs of patients with IPF should serve as a
driver for research in this area (11). IPF is a progressive, de-
bilitating disease and is an unmet clinical need, with patients
having an average life expectancy of only 3 y from diagnosis
(41). Because pulmonary macrophages are thought to drive the
pathologic condition (42), the identification of the receptor for
CXCL17 might provide a potential therapeutic target, and the
recent report that GPR35 is a CXCL17 receptor (23) therefore
deserves close scrutiny.
GPR35 mRNA has been reported to be expressed in the lungs,
stomach, small intestine, colon, and spleens of both humans and
mice (18) and also by leukocytes, including basophils, eosinophils,
mast cells (21), and iNKT cells (43). As such, GPR35 has
attracted attention as a therapeutic target for the treatment of
disorders including hypertension, ulcerative colitis, and asthma
(15). The role of GPR35 in this latter disease is of particular in-
terest because a number of medications prescribed to stabilize
mast cells (including lodoxamide, bufrolin, amlexanox, and
pemirolast) have been found by MacKenzie et al. (22) to activate
GPR35 with robust efficacy. Using HEK293 T transfectants
expressing various species orthologs of GPR35 or either the short
and longer isoforms of human GPR35, we were unable to show
any activity of CXCL17 at the receptor in assays of GPR35 ac-
tivation, including b-arrestin-2 recruitment or IP1 production
(Figs. 1, 2). While our manuscript was in revision, Park et al. (44)
reported that GPR35 expressed in HEK293 T cells was unable to
be activated by CXCL17 as deduced by an AP-TGFa shedding
assay, supportive of our data.
Using the L1.2 cell line as a background in which to successfully
express an HA-tagged variant of GPR35, we observed migration of
FIGURE 7. Analysis of the migration of PGE2-
treated THP-1 cells along CXCL17 gradients fol-
lowing pretreatment with the GPR35 antagonist
ML145. (A)–(C) show the paths traveled by indi-
vidual cells in response to the stimuli indicated. (A)
and (B) show the responses of cells pretreated with
the vehicle DMSO, whereas data in (C) show the
responses of cells pretreated with the GPR35 an-
tagonist ML145 at a final concentration of 1 mM.
Data were pooled from three experiments, with
four videos analyzed per condition in each exper-
iment. The total number of cells tracked for each
condition are shown in the top right hand corner of
the panels. (D) shows the mean FMI‖6 SEM of the
data shown in (A)–(C). Statistical differences be-
tween nonstimulus and the indicated stimuli were
confirmed by a one-way ANOVAwith Bonferroni’s
multiple comparisons test. ****p , 0.0001.
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GPR35 transfectants at a singular concentration of 1 mMCXCL17,
which trended toward significance when compared with basal
migration. However, the responses of the parental cell line were of
a similar potency and efficacy, suggesting that this weak response
was not mediated by the GPR35 introduced into the cells. Pre-
sumably, this endogenous CXCL17 receptor is able to recognize
the human CXCL17 used in this study, which is 71% identical to
the mouse ortholog. In contrast to a previous report (23), we were
unable to observe intracellular calcium flux in L1.2 transfectants
stably expressing 3xHA-GPR35 in response to a 100-nM con-
centration of CXCL17. The reasons for this are unclear. It is
possible that the L1.2 cell line, although like Ba/F3 a mouse B cell
line, does not provide a cellular background in which GPR35 can
efficiently couple to the intracellular signaling machinery. This
would be in contrast to the many other chemokine receptors we
and others have successfully expressed in the L1.2 cell line.
Similarly, the N-terminal 3xHA tag used by us, but not by
Maravillas-Montero and colleagues, has the potential to interfere
with chemokine binding and presentation by GPR35, although
again, we and others have expressed a variety of epitope-tagged
chemokine receptors with little adverse effect on receptor function.
Using the TAXIScan system to assess cell migration in real time,
THP-1 cells trended toward significant levels of migration along gra-
dients generated by the addition of 1 mM CXCL17 to the TAXIScan
chamber. This was markedly potentiated by overnight culture with
PGE2, in agreement with the findings of Maravillas-Montero et al.
(23). A previous manuscript reported that rat CXCL17 expressed in
HEK293 cells undergoes additional N-terminal cleavage, generating an
N-terminally truncated species with increased efficacy in chemotaxis
assays (45). Given that CXCL17 is associated with mucosal tissues and
FIGURE 8. Analysis of the migration of mono-
cytes along CXCL17 gradients following pretreat-
ment with the GPR35 antagonist ML145. (A)–(D)
show the paths traveled by individual cells in re-
sponse to the stimuli indicated. (A) and (B) show
the responses of cells pretreated with the vehicle
DMSO, whereas data in (C) and (D) show the re-
sponses of cells pretreated with the GPR35 antag-
onist ML145 at a final concentration of 1 mM. Data
were pooled from four experiments, with three
movies analyzed per condition in each experiment.
The total number of cells tracked for each condi-
tion are shown in the top right hand corner of the
panels. (E) shows the mean FMI‖ 6 SEM of the
data shown in (A)–(D).
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that mast cell chymase has been shown to cleave the N-termini of the
chemokines CCL15 and CCL23 and increase their potency and effi-
cacy (40), we tested the postulate that chymase might enhance the
potency and efficacy of CXCL17 for PGE2-treated THP-1 cells.
However, despite obvious cleavage of CXCL17 by mast cell chymase,
we failed to see any significant effect of cleavage upon the potency or
efficacy of CXCL17 in Boyden chamber chemotaxis assays. It remains
to be seen whether other proteases are able to cleave CXCL17 into a
more potent, active form.
Freshly isolated monocytes were unresponsive to CXCL17 in
TAXIScan assays, in keeping with the need to treat the THP-1 cells
with PGE2 to observe robust migration. However, this is in con-
trast to a previous report in which CD14+ cells from a mixture of
PBMCs were reported to be recruited by 250-nM–1-mM concen-
trations of CXCL17 (8). It should be noted that the recombinant
CXCL17 used in that study was generated in house and, unlike the
CXCL17 used in this study, contained a His tag, which may have
influenced receptor binding. Curiously, the authors of that study
FIGURE 9. CXCL17 undergoes cleavage by mast cell chymase with little effect upon potency or efficacy in chemotaxis assays. (A) shows an alignment
of the mature forms of human CXCL17, CCL15, and CCL23. The site of chymase cleavage of CCL15 and CCL23 is shown by a filled triangle. (B) shows
the cleavage of CCL15 and CCL23 following an 18 hr incubation with chymase. Proteins were separated by SDS-PAGE and visualized by Coomassie
Brilliant Blue staining (n = 3). (C) and (D) show the relative potency and efficacy of cleaved and uncleaved CCL15 (C) and CCL23 (D) in Boyden chamber
chemotaxis assays using CCR1 transfectants (n = 3). (E) shows the cleavage of CXCL17 following an 18 h incubation with chymase. Proteins were
separated by SDS-PAGE and visualized by Coomassie Blue staining (n = 3). (F) shows the relative potency and efficacy of cleaved and uncleaved CXCL17
in Boyden chamber chemotaxis assays using PGE2-treated THP-1 cells (n = 4).
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reported that PGE2 treatment of monocytes significantly reduced
the responses of cells to their recombinant CXCL17, in stark
contrast to the observations of us and Maravillas-Montero and
colleagues. McCully et al. (46) have previously shown that PGE2
is an essential component of the epidermis-conditioned media,
responsible for increasing T cell responses to the chemokine
CCL1 and subsequent homing of these cells to the skin. The ef-
fects of PGE2 in that experimental system are mediated by the
EP4 receptor and result in elevated intracellular cAMP levels,
which can be mimicked by culture of the cells with forskolin. In
those studies, in combination with metabolites of vitamin D3,
PGE2 had the effect of increasing the cell surface expression of
CCR8, the cognate receptor for CCL1 (46).
It is tempting to speculate that in our system, the overnight
culture of THP-1 cells with PGE2 results in elevated levels of a
CXCL17 receptor and increased chemotactic responsiveness to
CXCL17. Indeed, this was the postulate of Maravillas-Montero
and colleagues when they showed that GPR35 mRNA levels were
elevated by such treatment. However, in that study, the authors
failed to directly show that the induction of GPR35 was directly
responsible for the increased responsiveness to CXCL17 (23). In
our study, using a well-characterized antagonist of GPR35 that
has nanomolar potency at GPR35, we were able to show that
chemotaxis of PGE2-treated THP-1 cells toward a source of
CXCL17 was unimpeded by GPR35 blockade. These data are
also in agreement with those of Park et al. (44), who, in a recent
study using the alternative small molecule GPR35 antagonist
CID2745687, showed that THP-1 cell migration to CXCL17 was
independent of GPR35. Taken together with our transfectant data,
which was overwhelmingly negative in terms of finding CXCL17
activity at GPR35, we must therefore conclude that GPR35 is not
a bona fide receptor for CXCL17 and that this chemokine remains
an orphan. As such, efforts to identify the CXCL17 receptor
should be resumed with intensity.
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